A phase II Clinical Trial on the use of ARA 290 for the treatment of Diabetic Macular Oedema
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2017
At a glance
- Drugs Cibinetide (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 02 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 10 May 2016 Status changed from not yet recruiting to recruiting as per Ariam Pharmaceuticals media release.
- 10 May 2016 According to Ariam Pharmaceuticals media release, company has enrolled the first patient.